Pharmacy News

As a results, NHS Practitioner Health plans to recruit around 40 additional clinicians and grow its therapist network.

AFib is the most common type of irregular heartbeat and is a significant risk factor for stroke.

The drug is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from the flu.

The approval is for severe osteoporosis in postmenopausal women at high risk of fracture.

The drug is an anticoagulant that targets Factor Xa, approved to prevent atherothrombotic events in coronary artery disease.

The Progenics drug is currently not approved for any indication outside of the US.

24% of asthma patients have difficult-to-treat or severe versions of the disease.

Only half of patients who are diagnosed as young onset patients are offered a genetic test on diagnosis.

UPS, DFDS and Biocair will handle express freight services to deliver medicines and medical products within 24 to 48 hours in the event of a no-deal Brexit.

AstraZeneca and Daiichi Sankyo's trastuzumab deruxtecan has taken a step closer to US approval having been accepted for priority review by the US Food and Drug Administration (FDA) for breast cancer.

The 2019 Medical & Scientific Excellence Awards will be closing for entry on October 31.

58,000 more children were recorded as obese than last year.

The system aims to help paramedics on the ground to make the right clinical decisions instead of taking the patient to A&E.

There is currently a “critical need” for additional treatment options for atopic dermatitis.

Professor Sir Mike Richards makes several recommendations, with a key focus on improving uptake.

The campaign is aimed at students who don't know what they could be buying online.

The approval marks the first new class of acute migraine treatment approved by the FDA in more than two decades.

Performance statistics throughout the last year have shown “strain on an already stretched system."

The process could pave the way for more rapid delivery of individualised treatments.

The study is still ongoing, with patients participating in a 48-week safety follow-up period.